Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure

NCT01748240 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

OTHER

Sponsor class

Stopped inefficiency

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine and oral vorinostat

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]